focus -WSS

focus

author：hotspot 2025-09-30 14:57:48 - browse：53588

Outgoing Bristol CEO Giovanni Caforio Emilie Pickering for STAT

It’s changing of the guard time at pharmaceutical giant Bristol Myers Squibb. On Wednesday, CEO Giovanni Caforio will step down. He’ll be replaced by Christopher Boerner, who is currently chief operating officer.

When Caforio took over in May 2015, Bristol was known as a big pharmaceutical firm with the high-flying stock of a biotechnology company, largely due to its role as the company that brought cancer immunotherapy to market. But Bristol stumbled in 2016 when its immunotherapy Opdivo failed to help patients with non-small cell cancer more than chemotherapy. Opdivo remained a big seller, but its failure allowed Merck’s rival Keytruda to move into position to become the best-selling medicine in the world. In 2019, Caforio tried to flip the script, buying the biotech Celgene for $74 billion.

STAT recently sat down with Caforio, 59, to look back on what went wrong and right with his tenure. He also reflected on what it meant to be a physician — and the son of a physician. “We were speaking about patient stories over lunch and dinner, when I was a kid, and I think that drove my passion for medicine,” he said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Case highlights the risks of experimental stem cell therapy

explore

WSS

St. Louis police protesters begin picking up checks in $4.9 million settlement

With measles on the rise, a personal story of a devastating disease

Wearables generate powerful data but its not useful to doctors, yet

Doctors are clamoring for more clarity on Paxlovid prescribing

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

Readout LOUD podcast: Live from STAT Breakthrough Summit West

explore

focus

entertainment

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Failure, not just success, should guide future doctors

After affirmative action ruling, medical educators look to 'holistic review'

Arc Institute generative AI designs new CRISPR systems

Peter Hotez and the public health issue of online harassment

Slovenia has suffered its worst

Apple is now the first public company to be valued at $3 trillion

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Drug repurposing or repositioning? The language matters

Pennsylvania man bitten on the head by bear during attack in his garage

focus

McConnell is warmly embraced by Kentucky Republicans amid questions about his health

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Doctors are clamoring for more clarity on Paxlovid prescribing

Tuberculosis patients need more than just free medication

Slovenia has suffered its worst

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

explore

focus

knowledge

explore